Analytical Chemistry and Pharmacology Core Facility The goal of this core is to support the translational development of small molecule and nanoparticle anticancer agents via analytical chemistry and pharmacologic infrastructure and methodologies. The expansion of the MolecularTherapeutics Program, development of preclinical models used to evaluate anticancer agents and the opening of new North Carolina Cancer Hospital's Clinical Trials Unit created the demand for applied pharmacology services. The recruitment of Dr. Zamboni and the substantial investment of cancer center institutional funds launched the core and its operations. This new core is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab (opened in March'09) and the UNC GLP Bioanalytical Facility (will open in Feb'10). The technologies and resources offered by this core were not previously available at UNC. Moreover, the UNC GLP Bioanalytical Facility is one of the few such GLP labs that exist in an academic center. The core resources will expand researchers'horizons and funding by providing outstanding expertise in performing analytical and pharmacology studies, providing the highest quality of data and performing these studies in a cost effective manner. The core's sen/ices consist of: analytical studies at GLP and non-GLP levels;development of drug formulations;development and validation of analytical assays In biological matrices;sample analysis;pharmacokinetic and pharmacodynamic data analysis;and specialized methods for nanoparticle pharmacology. An example of this is the collaboration with Drs. Sharpless, Collichio and Ollila, where we are currently evaluating the factors affecting the tumor delivery of anticancer agents in xenograft and genetically engineered mouse models (GEMM) of melanoma and in patients with cutaneous melanoma. Future plans are to expand the research of UNC LCCC members and use the resources of this core to recruit novel anticancer agents to UNC. The core requests $160,846, representing 15% of its operating costs;Cancer Center members constitute 96% of the core's users. This new core will be a tremendous asset to the center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-36
Application #
8376360
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
36
Fiscal Year
2012
Total Cost
$239,629
Indirect Cost
$76,452
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ziehr, Benjamin; Vincent, Heather A; Moorman, Nathaniel J (2016) Human Cytomegalovirus pTRS1 and pIRS1 Antagonize Protein Kinase R To Facilitate Virus Replication. J Virol 90:3839-48
Xiao, Ping-Jie; Mitchell, Angela M; Huang, Lu et al. (2016) Disruption of Microtubules Post-Virus Entry Enhances Adeno-Associated Virus Vector Transduction. Hum Gene Ther 27:309-24
White, Alexandra J; Bradshaw, Patrick T; Herring, Amy H et al. (2016) Exposure to multiple sources of polycyclic aromatic hydrocarbons and breast cancer incidence. Environ Int 89-90:185-92
Xu, Yang; Chaudhury, Arindam; Zhang, Ming et al. (2016) Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest 126:2678-88
He, Zhijian; Wan, Xiaomeng; Schulz, Anita et al. (2016) A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials 101:296-309
Moracco, Kathryn E; Morgan, Jennifer C; Mendel, Jennifer et al. (2016) "My First Thought was Croutons": Perceptions of Cigarettes and Cigarette Smoke Constituents Among Adult Smokers and Nonsmokers. Nicotine Tob Res 18:1566-74
Park, Eliza M; Deal, Allison M; Check, Devon K et al. (2016) Parenting concerns, quality of life, and psychological distress in patients with advanced cancer. Psychooncology 25:942-8
Ohkuni, Kentaro; Takahashi, Yoshimitsu; Fulp, Alyona et al. (2016) SUMO-Targeted Ubiquitin Ligase (STUbL) Slx5 regulates proteolysis of centromeric histone H3 variant Cse4 and prevents its mislocalization to euchromatin. Mol Biol Cell :
Becker, Marc A; Ibrahim, Yasir H; Oh, Annabell S et al. (2016) Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. PLoS One 11:e0150564
Sin, Sang-Hoon; Kang, Sun Ah; Kim, Yongbaek et al. (2016) Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation. J Virol 90:2150-4

Showing the most recent 10 out of 897 publications